Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 10/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 5/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21373319 | 1.00 | WEE1 (0.59) | WEE1KCNH2BRD4EGFRSIK2 | |
| SCHEMBL29506459 | 0.95 | WEE1 (0.59) | WEE1KCNH2BRD4EGFRSIK2 | |
| SCHEMBL21373288 | 0.95 | WEE1 (0.59) | WEE1KCNH2BRD4EGFRSIK2 | |
| SCHEMBL21373403 | 0.93 | WEE1 (0.61) | WEE1KCNH2BRD4EGFRSIK2 | |
| SCHEMBL29506521 | 0.93 | WEE1 (0.61) | WEE1KCNH2BRD4EGFRSIK2 | |
| SCHEMBL21373416 | 0.92 | WEE1 (0.68) | WEE1KCNH2BRD4EGFRSIK2 | |
| SCHEMBL29506525 | 0.92 | WEE1 (0.68) | WEE1KCNH2BRD4EGFRSIK2 | |
| SCHEMBL21373301 | 0.92 | WEE1 (0.63) | WEE1KCNH2SIK2TNK2 | |
| SCHEMBL29506515 | 0.92 | WEE1 (0.63) | WEE1KCNH2SIK2TNK2 | |
| SCHEMBL21373390 | 0.91 | WEE1 (0.69) | WEE1KCNH2BRD4EGFRSIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118338905-A | Use of Wee1 kinase inhibitors in the treatment of cancer | 上海瑛派药业有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-117202908-A | Use of Wee1 kinase inhibitors in the treatment of cancer diseases | 上海瑛派药业有限公司 | 2023-12-08 | — | — | CN | claimed |
| WO-2023093840-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-06-01 | — | — | WO | claimed |
| WO-2022188802-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2022-09-15 | — | — | WO | claimed |
| CN-109906227-B | 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones | 上海瑛派药业有限公司 | 2022-03-11 | — | — | CN | claimed |
| WO-2025074275-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS AND WEE1 INHIBITORS | REPARE THERAPEUTICS, INC. (CA) | 2025-04-10 | — | — | WO | disclosed |
| CN-118338905-A | Use of Wee1 kinase inhibitors in the treatment of cancer | 上海瑛派药业有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-117202908-A | Use of Wee1 kinase inhibitors in the treatment of cancer diseases | 上海瑛派药业有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023093840-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-06-01 | — | — | WO | disclosed |
| WO-2022188802-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2022-09-15 | — | — | WO | disclosed |
| CN-109906227-B | 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones | 上海瑛派药业有限公司 | 2022-03-11 | — | — | CN | disclosed |